Synthesis and in-vitro cytotoxic evaluation of novel pyridazin-4-one derivatives

Archiv der Pharmazie

Volumn 343, Issue 5, 2010, Pages 310-313

  Mojahidi, Souad ^a   Rakib, El Mostapha ^a   Sekkak, Hanan ^a   Abouricha, Said ^a   Benchat, Nouredine ^b   Mousse, Hassan A ^a   Zyad, Abdelmajid ^a  

^a SULTAN MOULAY SLIMANE UNIVERSITY   (Morocco)

^b FACULTÉ DES SCIENCES   (Morocco)

Author keywords

2 Pyrone; Arylhydrazonopyranedione; Cytotoxic activity; Pyrazolo 4,3 c pyridazinone; Pyridazinone

Indexed keywords

1 (4 CHLORO PHENYL) 1,4 DIHYDRO 4 OXO 6 METHYL PYRIDAZINE 3 CARBOXYLIC ACID; 1 (4 FLUORO PHENYL) 1,4 DIHYDRO 4 OXO 6 METHYL PYRIDAZINE 3 CARBOXYLIC ACID; 1 (4 METHOXY PHENYL) 1,4 DIHYDRO 4 OXO 6 METHYL PYRIDAZINE 3 CARBOXYLIC ACID; 1 (4 METHYL PHENYL) 1,4 DIHYDRO 4 OXO 6 METHYL PYRIDAZINE 3 CARBOXYLIC ACID; 1 (4 NITRO PHENYL) 1,4 DIHYDRO 4 OXO 6 METHYL PYRIDAZINE 3 CARBOXYLIC ACID; 5 (4 FLUOROPHENYL) 6 METHYL 2H PYRAZOLO[4,3 C]PYRIDAZIN 3(5H) ONE; 5 (4 NITROPHENYL) 6 METHYL 2H PYRAZOLO[4,3 C]PYRIDAZIN 3(5H) ONE; ANTINEOPLASTIC AGENT; N ARYL 4 OXO 1,4 DIHYDRO PYRIDAZINE 3 CARBOXYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MASTOCYTOMA; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MOLECULAR STRUCTURE; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77951565351     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900290     Document Type: Article

References (17)

1. A. V. Velentza, M. S. Wainwright, M. Zasadzki, S. Mirzoeva, et al., Bioorg. Med. Chem. Lett. 2003, 13, 3465-3470.
2. C. G. Wermuth, J. J. Bourguignon, R. Hoffmann, R. Boigegrain, et al., Bioorg. Med. Chem. Lett. 1992, 2, 833-838;
3. J. M. Contreras, I. Parrot, W. Sippl, Y. M. Rival, C. G. Wermuth, J. Med. Chem. 2001, 44, 2707-2718.
4. J. M. Contreras, Y. M. Rival, S. Chayer, J. J. Bourguignon, C. G. Wermuth, J. Med. Chem. 1999, 42, 730-741.
5. M. Schmitt, J. J. Bourguignon, G. B. Barlin, L. P. Davies, Aust. J. Chem. 1997, 50, 779-785.
6. Y. Rival, R. Hoffmann, B. Didier, V. Rybaltchenko, et al., J. Med. Chem. 1999, 41, 311-317.
7. A. Coelho, E. Sotelo, N. Fraiz, M. Yáñez, et al., Bioorg. Med. Chem. Lett. 2004, 14, 321-324.
8. E. Sotelo, N. Fraiz, M. Yéñez, V. Terrades, et al., Bioorg. Med. Chem. 2002, 10, 2873-2882.
9. A. Crespo, C. Meyers, A. Coelho, E. Sotelo, et al., Bioorg. Med. Chem. Lett. 2006, 16, 1080-1083.
10. L. Betti, L. Zanelli, G. Giannaccini, F. Manetti, et al., Bioorg. Med. Chem. 2006, 14, 2828-2836 (and references cited therein).
11. H. Frank, G. Heinisch in Pharmacologically Active Pyridazines, Part 2 (Eds.: G. P. Ellis, D. K. Luscombe), Progress in Medicinal Chemistry, Elsevier, Amsterdam, 1992, Vol. 29, pp. 141-183.
12. V. D. Piaz, C. Vergelli, M. P. Giovannoni, A. M. A. Scheideler, et al., Il Farmaco 2003, 58, 1063-1071;
13. M. Gokce, D. Dogruer, M. F. Sahin, Il Farmaco 2001, 56, 233-237.
14. E. M. Rakib, S. Abouricha, A. Hannioui, N. Benchat, et al., J. Iran. Chem. Soc. 2006, 3 (3), 272-276.
15. S. Abouricha, E. M. Rakib, N. Benchat, M. Alaoui, et al., Synth. Commun. 2005, 35 (16), 2213-2221.
16. J. F. Morgan, J. Am. Chem. Soc. 1948, 70, 2253-2254.
17. T. Mossman, J. Immunol. Methods 1983, 65, 55-63.